IraM Bernstein

IraM Bernstein

Auto-generated profile, based on publicly available information

IraM Bernstein

University of Vermont College of Medicine, Burlington, VT

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2001 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
IBI Bernstein
I Bernstein
To determine the time course of plasma volume expansion in early pregnancy. We prospectively measured plasma volume by Evans blue dye dilution during the menstrual (cycle day 2--3), follicular (cycle day 9--10), and luteal phases (cycle day urinary leutinizing hormone [LH] surge plus 9--10) of the menstrual cycle and at three additional time points (LH surge + 16 days, LH surge + 28 days, and LH surge + 70 days) in women achieving pregnancy. Twenty-one subjects were examined during 38 menstrual cycles to establish baseline menstrual cycle data. Ten subjects conceived within 1 year of menstrual cycle studies. All ten pregnancies were viable and reached the third trimester. Analyses used repeated-measures analysis of variance with P <.05 accepted for significance. Mean plasma volume was found to change significantly across the period of observation (P <.008) in those who conceived. Plasma volume at LH surge + 70 days (12 menstrual weeks, 2320 +/- 280 mL) was greater than either menstrual cycle estimates or early pregnancy estimates of plasma volume. There was no difference in plasma volume at LH surge + 16 days (2077 +/- 288 mL) or LH surge + 28 days (2010 +/- 271 mL) compared with menstrual cycle measurements during the menstrual phase (2156 +/- 292 mL), follicular phase (2036 +/- 280 mL), and luteal phase (2120 +/- 425 mL). There was no significant difference between those who conceived and those who did not in their mean menstrual cycle plasma volume. Plasma volume expansion in early human pregnancy cannot be identified until after the sixth menstrual week. By 12 menstrual weeks, plasma volume has expanded by approximately 14% +/- 12% (mean +/- SD) over follicular phase measurements.

1 August 1998 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
IBI Bernstein
I Bernstein
We present a theorized mechanism for the development of preeclampsia, suggesting that one important underlying pathophysiologic mechanism is intolerance to volume expansion. The stage is set for this intolerance by chronic volume constriction, which leads to a requirement for increased basal peripheral vasoconstrictor tone to maintain blood pressure and allow for continued perfusion of the upright hominid head. In pregnancy, volume expansion signaled by the placenta cannot be accommodated by the constricted vascular system. The inability of the normally adaptive endothelial vasodilatory mechanisms to overcome the chronic vasoconstrictor tone leads to endothelial damage, exacerbation of vasoconstriction, and clinical hypertension. Disease resolution, characterized by diuresis, occurs with the elimination of the placenta-derived drive to retain volume. The reason preeclampsia does not recur uniformly with subsequent pregnancy is permanent restructuring of the maternal cardiovascular system with pregnancy that allows for greater plasma volume expansion in future gestations.

1 April 2002 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
IBI Bernstein
I Bernstein
To estimate the time course of human uterine artery vascular adaptation through the menstrual cycle into early pregnancy. We prospectively measured the uterine artery pulsatility index, peak systolic velocity, and volumetric blood flow during the menstrual cycle and at 4, 6, and 12 weeks of pregnancy in women who conceived. Upper extremity radial artery hemodynamic changes were examined as a control vessel. Ten subjects conceived within 12 months of menstrual cycle studies. Analyses were performed using repeated measures analysis of variance with P <.05 accepted for significance. In women who conceived, uterine artery peak systolic velocity demonstrated a significant increase during the period of observation, which began after cycle day 10 (0.36 x 0.02 meters per second) of the menstrual cycle and continued though 12 menstrual weeks (1.05 +/- 0.10 meters per second, P <.001). Uterine artery pulsatility index decreased significantly during the observation window from 3.0 +/- 0.2 in the follicular phase to 1.6 +/- 0.2 at 12 menstrual weeks (P <.001). Blood flow in the uterine artery increased significantly from cycle day 10 (22.2 +/- 1.8 mL per minute) to 12 menstrual weeks' gestation (150.2 +/- 40.3 mL per minute, P <.001). These patterns were significantly different from the patterns observed for the radial artery. Uterine artery hemodynamic adaptation in early pregnancy follows a continuum established during the menstrual cycle. These adaptations result in decreased uterine artery impedance and increased blood flow. These changes differ from those observed in the upper extremity radial artery (control vessel) suggesting independence of regional pelvic and systemic hemodynamic adaptations.

1 August 1998
Verified
Journal Article
Closed access
IBIraM Bernstein
IraM Bernstein
WZWilliam Ziegler
William Ziegler
WSWilliamS Stirewalt
WilliamS Stirewalt
JBJohn Brumsted
John Brumsted
KWKen Ward
Ken Ward
Objective: To determine if nonpregnant plasma volume is altered in women who are homozygous for the T 235 coding angiotensinogen allele, which predisposes women to an increased risk of preeclampsia. Methods: We measured plasma volume by Evans blue dilution and analyzed it as a function of angiotensinogen genotype in 15 nulligravid women during midfollicular phase of 26 menstrual cycles. Eleven women were evaluated during two cycles, and four women were evaluated in one cycle. Fourteen women were white, and one was Asian. No subjects had illnesses or were taking medication. The range of body mass index (BMI [kg/m2]) was 20.2–31.0. Plasma volume (mL) was reported as plasma volume divided by BMI to control for variations in body sizes. Statistical analysis was performed by analysis of variance with post hoc testing using Fisher least significant difference test for multiple comparisons (P < .05 accepted for significance). Results: Angiotensinogen genotype analysis showed five women homozygous for M 235, three women homozygous for T 235, and seven women who were heterozygous (MT 235). T 235 homozygotes had significantly lower plasma volume divided by BMI compared with women who were homozygous for M 235 and women who were heterozygous for MT 235 (mean + standard deviation [SD] [71.2 + 8.8, 86.6 + 5.2, 95.8 + 15.6, respectively, P < .05]). There was a tendency toward higher plasma volume in heterozygote MT 235 compared with homozygote M 235 carriers, but it was not statistically significant. Conclusion: We conclude that the homozygous T 235 coding angiotensinogen genotype is associated with reduced plasma volume in nulligravid women during the follicular phase of the menstrual cycle compared with M 235 homozygotes and heterozygotes. This association of the T 235 coding genotype might contribute to fetal growth restriction in preeclampsia.

1 November 1997 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
IBI Bernstein
I Bernstein
MGM Goran
M Goran
KCK Copeland
K Copeland
To examine the relationship of multiple maternal and cord blood correlates of newborn size to determine the relative strength of the insulin-like growth factor-I association. Thirty-seven venous cord blood specimens were obtained at the time of delivery. Ponderal index and birth weight percentile were calculated at birth. Neonatal length estimates were performed with a measuring board. All mothers were nonsmokers and had normal glucose tolerance. There was a wide range of maternal prepregnancy body mass indexes (BMI) (19.6-43.4). Neonates had a wide range of ponderal indexes (2.12-2.75) and birth weight percentiles (7-99th percentile). Univariate correlation coefficients were calculated to determine simple relationships. Stepwise linear regression analyses were performed to determine the relative contribution of potential explanatory variables to both ponderal index and birth weight percentile. Potentially explanatory independent variables included maternal prepregnancy BMI, weight gain in pregnancy, and maternal insulin sensitivity at 32 weeks' gestation. Maternal insulin sensitivity was estimated using the minimal model technique. Neonatal variables included sex, cord blood albumin, insulin, insulin-like growth factor-I, insulin-like growth factor-binding protein-1, and insulin-like growth factor-binding protein-3. Significant positive univariate correlations were identified between cord blood insulin-like growth factor-I and insulin-like growth factor-binding protein-3 with neonatal ponderal index and birth weight percentile. Maternal insulin sensitivity demonstrated a negative correlation with birth weight percentile (r = -.35, P < .05). Cord blood insulin correlated positively with birth weight percentile (r = .32, P < .05). There were no significant associations of cord blood insulin-like growth factor-binding protein-1 or albumin with either index of newborn size. Stepwise logistic regression analysis demonstrated an independent association of insulin-like growth factor-I with ponderal index (r2 = .41, P < .001). Both insulin-like growth factor-I and male sex were associated independently with birth weight percentile (r2 = .38, P < .001). No additional independent variables contributed to the prediction of ponderal index or birth weight percentile. These data support a unique relationship between cord blood insulin-like growth factor-I and newborn size under normal growth conditions. This is manifest by the strength and independence of the association between insulin-like growth factor-I and neonatal birth weight percentile ponderal index.

1 December 1997 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
IBI Bernstein
I Bernstein
To test the hypothesis that an elevated amniotic fluid glycine-valine ratio predicts neonatal morbidity in growth-restricted newborns. Amniotic fluid (AF) was collected from 122 third-trimester pregnancies (range 31-39 weeks), 49 of which were complicated by fetal growth restriction. Amino acid analysis was performed by high-pressure liquid chromatography. Glycine-valine ratios were compared between normal and growth-restricted fetuses. Neonatal morbidity within the group of growth-restricted fetuses was characterized by evaluation of neonatal hypoglycemia, arterial cord blood gas analysis, and birth weight percentile. We also examined the correlation of AF glycine-valine ratio to the umbilical artery resistance index. The median interval between AF sampling and delivery was 1 day (range 0-8 days). Analyses were performed by Student t test, chi 2 with Yates correction, or simple correlation when appropriate. P < .05 was considered significant. Growth-restricted fetuses have a significantly elevated AF glycine-valine ratio compared with control subjects (3.31 +/- 1.06 versus 2.61 +/- 0.77, respectively, P < .001). There was no association of the glycine-valine ratio with gestational age for either group. An elevated glycine-valine ratio was not associated with neonatal hypoglycemia within the growth-restricted group (hypoglycemia: [n = 16] 3.19 +/- 1.07; no hypoglycemia: (n = 30) 3.44 +/- 1.09). There were no significant correlations of glycine-valine ratio with arterial cord blood pH (r = -0.10), oxygen pressure (r = 0.04), or base deficit (r = 0.12). There were no significant correlations of glycine-valine ratio and birth weight percentile (r = -.24) or umbilical artery resistance index (r = -.14). Amniotic fluid glycine-valine ratio is elevated in growth-restricted fetuses compared with control fetuses. However, the level of glycine-valine elevation is not associated with neonatal morbidity related to hypoglycemia, arterial cord blood gas abnormalities, or birth weight percentile.